Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Flows and flaws in primary central nervous system lymphoma.

Literature DB >> 20700952

Flows and flaws in primary central nervous system lymphoma.

Andrés J M Ferreri, Gerald Illerhaus, Emanuele Zucca, Franco Cavalli.

Abstract

Entities: Disease Mutation

Mesh：

Substances：

Year: 2010 PMID： 20700952 DOI： 10.1038/nrclinonc.2010.9-c1

Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN： 1759-4774 Impact factor: 66.675

× No keyword cloud information.

10 in total

Review 1. State-of-the-art therapeutics: diffuse large B-cell lymphoma.

Authors: Bertrand Coiffier
Journal: J Clin Oncol Date: 2005-09-10 Impact factor: 44.544

2. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report.

Authors: Ulrich Herrlinger; Wilhelm Küker; Martin Uhl; Hans-Peter Blaicher; Hans-Otto Karnath; Lothar Kanz; Michael Bamberg; Michael Weller
Journal: Ann Neurol Date: 2005-06 Impact factor: 10.422

3. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system.

Authors: Gerald Illerhaus; Fabian Müller; Friedrich Feuerhake; Arnd-Oliver Schäfer; Christoph Ostertag; Jürgen Finke
Journal: Haematologica Date: 2008-01 Impact factor: 9.941

4. Hematology: Trials and tribulations in primary CNS lymphoma.

Authors: Stephen M Ansell; S Vincent Rajkumar
Journal: Nat Rev Clin Oncol Date: 2010-03 Impact factor: 66.675

5. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study.

Authors: M Montemurro; T Kiefer; F Schüler; H K Al-Ali; H-H Wolf; R Herbst; A Haas; K Helke; A Theilig; C Lotze; C Hirt; D Niederwieser; M Schwenke; W H Krüger; G Dölken
Journal: Ann Oncol Date: 2006-12-21 Impact factor: 32.976

Review 6. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines.

Authors: D D Correa; L Maron; H Harder; M Klein; C L Armstrong; P Calabrese; J E C Bromberg; L E Abrey; T T Batchelor; D Schiff
Journal: Ann Oncol Date: 2007-02-06 Impact factor: 32.976

7. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

Authors: Andrés J M Ferreri; Michele Reni; Marco Foppoli; Maurizio Martelli; Gerasimus A Pangalis; Maurizio Frezzato; Maria Giuseppina Cabras; Alberto Fabbri; Gaetano Corazzelli; Fiorella Ilariucci; Giuseppe Rossi; Riccardo Soffietti; Caterina Stelitano; Daniele Vallisa; Francesco Zaja; Lucía Zoppegno; Gian Marco Aondio; Giuseppe Avvisati; Monica Balzarotti; Alba A Brandes; José Fajardo; Henry Gomez; Attilio Guarini; Graziella Pinotti; Luigi Rigacci; Catrina Uhlmann; Piero Picozzi; Paolo Vezzulli; Maurilio Ponzoni; Emanuele Zucca; Federico Caligaris-Cappio; Franco Cavalli
Journal: Lancet Date: 2009-09-18 Impact factor: 79.321

8. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.

Authors: Tracy Batchelor; Kathryn Carson; Alison O'Neill; Stuart A Grossman; Jane Alavi; Pamela New; Fred Hochberg; Regina Priet
Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544

9. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.

Authors: Andrés J M Ferreri; Jean-Yves Blay; Michele Reni; Felice Pasini; Michele Spina; Achille Ambrosetti; Antonello Calderoni; Andrea Rossi; Vittorio Vavassori; Annarita Conconi; Liliana Devizzi; Françoise Berger; Maurilio Ponzoni; Bettina Borisch; Marianne Tinguely; Michele Cerati; Mario Milani; Enrico Orvieto; Juvenal Sanchez; Christine Chevreau; Stefania Dell'Oro; Emanuele Zucca; Franco Cavalli
Journal: J Clin Oncol Date: 2003-01-15 Impact factor: 44.544

Review 10. High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions.

Authors: Andrés J M Ferreri; Roberto Crocchiolo; Andrea Assanelli; Silvia Govi; Michele Reni
Journal: Leuk Lymphoma Date: 2008-11

10 in total

33 in total

Review 1. Decision for cell fate: deubiquitinating enzymes in cell cycle checkpoint.

Authors: Key-Hwan Lim; Myoung-Hyun Song; Kwang-Hyun Baek
Journal: Cell Mol Life Sci Date: 2016-01-13 Impact factor: 9.261

Review 2. Current application of proteomics in biomarker discovery for inflammatory bowel disease.

Authors: Patrick Py Chan; Valerie C Wasinger; Rupert W Leong
Journal: World J Gastrointest Pathophysiol Date: 2016-02-15

Review 3. 3D in vitro modeling of the central nervous system.

Authors: Amy M Hopkins; Elise DeSimone; Karolina Chwalek; David L Kaplan
Journal: Prog Neurobiol Date: 2014-11-22 Impact factor: 11.685

4. Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids.

Authors: Rie Ouchi; Shodai Togo; Masaki Kimura; Tadahiro Shinozawa; Masaru Koido; Hiroyuki Koike; Wendy Thompson; Rebekah A Karns; Christopher N Mayhew; Patrick S McGrath; Heather A McCauley; Ran-Ran Zhang; Kyle Lewis; Shoyo Hakozaki; Autumn Ferguson; Norikazu Saiki; Yosuke Yoneyama; Ichiro Takeuchi; Yo Mabuchi; Chihiro Akazawa; Hiroshi Y Yoshikawa; James M Wells; Takanori Takebe
Journal: Cell Metab Date: 2019-05-30 Impact factor: 27.287

5. Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1.

Authors: H-B Qiu; W Zhuang; T Wu; S Xin; C-Z Lin; H-L Ruan; X Zhu; M Huang; J-L Li; X-Y Hou; Z-W Zhou; X-D Wang
Journal: Pharmacogenomics J Date: 2017-08-01 Impact factor: 3.550